Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

Name: Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
Published: 2018
License: Public Domain

Tesaro, Inc. · 2018

ClinicalTrials.gov · Datasets · License: Public Domain · 2018

Open Source ↗

ovarian-cancer

ovarian neoplasm, poly-adp-ribose polymerase (parp) inhibitor, ovarian cancer, niraparib, bevacizumab, tsr-042, neoadjuvant treatment, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

Related documents